Nils Lonberg - 09 Jun 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: Director
Issuer ticker: BCAX
Reported as of: 09 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2025, 16:29:32 UTC
Prior SEC filing: 16 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact

Key filing fact

Nils Lonberg filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 10 Jun 2025.

Key facts

This page summarizes Nils Lonberg's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2025, 16:29.

Change

Previous filing in this sequence was filed on 16 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001214506 Primary reporting owner

LONBERG NILS

Relationship: Director
Address: BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON
Signature: /s/ Lara Meisner, Attorney-in-Fact
Signature date: 10 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,746
Change %
Price: $0.000000
Shares after: 23,746
Date: 09 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,746
Exercise price: $11.48
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.